Guangdong Hou

Xijing Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Jianlin Yuan

Sichuan University

Fuli Wang

Air Force Medical University

Yu Zheng

Air Force Medical University

Ming Gao

Affiliated Hospital of Jining Medical University

Wanxiang Zheng

Army Medical University

Di Wei

Xijing Hospital

Jiarui Yuan

Air Force Medical University

Ping Meng

Guangzhou Medical University

Niuniu Hou

Air Force Medical University

Xinlong Dun

Air Force Medical University

Cooperative Institutions

Air Force Medical University

141

Xijing Hospital

112

National Institute of Diabetes and Digestive and Kidney Diseases

ProQuest (United States)

Chinese Academy of Medical Sciences & Peking Union Medical College

Sun Yat-sen University

Chinese Academy of Sciences

Liechtenstein Institute

Capital Medical University

Fudan University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Efficacy and safety of adjuvant targeted therapy for patients with non-distant metastasis renal cell carcinoma

Zhonghua miniao waike zazhi (2019)

Yu Zheng Di Wei Guangdong Hou Geng Zhang

Objective To evaluate the efficacy and adverse events of adjuvant targeted therapy for non-distant metastatic renal cell carcinoma (ndmRCC). Methods A comprehensive literature search was conducted in PubMed, SpringerLink, Web of Science, and the Cochrane Library. All clinical randomized controlled trials on adjuvant targeting therapy for ndmRCC were retrieved. Literature screening, data extraction and literature quality evaluation were conducted by three researchers independently, and meta-analysis was performed using Review Manager Version 5.3. Outcomes we were interested in included progression-free survival (PFS), overall survival (OS), and adverse events. Results A total of 4 RCTs with 5 studies and 4 944 ndmRCC patients were selected for meta-analysis. Targeted adjuvant therapy improved the PFS of ndmRCC patients. The hazard ratio (HR) was 0.92(95%CI0.85-1.00, P =0.05) between the targeted therapy group and the placebo group. With the extension of follow-up, this effect was more significant, and the HR was 0.89(95%CI0.81-0.97, P=0.01). However, targeted adjuvant therapy did not extend the OS of ndmRCC patients, and the HR was 0.92(95%CI0.81-1.05, P=0.22). Compared with the placebo, targeted adjuvant therapy increased the incidence of adverse events and the number of patients who had to discontinue because of adverse events was also increased. The odds ratios were 6.03(95%CI5.30-6.86, P<0.001) and 7.65(95%CI6.31-9.26, P<0.001), respectively. Conclusions Targeted adjuvant therapy can improve the PFS of ndmRCC patients after surgery, but it cannot improve the OS. At the same time, it increases the incidence of adverse events. Key words: Renal cell carcinoma; Targeted adjuvant therapy; Meta-analysis

Adjuvant Therapy

Targeted Therapy

10.3760/cma.j.issn.1000-6702.2019.03.003

Cite

Citations (0)

Development and Validation of the First Multi-Racial Prognostic Nomogram for Patients with Bone Metastatic Prostate Cancer Worldwide

SSRN Electronic Journal (2019)

Guangdong Hou Yu Zheng Di Wei Jingyang Tian Fuli Wang

Background: The independent prognostic factors for survival of patients with bone metastatic prostate cancer (PCa) remain controversial; Besides, a nomogram for application to multiple ethnicities has yet to be established. We aimed to build a generic nomogram to predict the prognosis of bone metastatic PCa.Methods: The independent prognostic factors for survival were identified, and the nomogram was further developed in a retrospective study of 1,556 patients with bone metastatic PCa registered in the Surveillance, Epidemiology and End Results (SEER) database. The discriminative ability of the nomogram was assessed by C-index (concordance index) and ROC (receiver operating characteristic) curve analysis, whereas its predictive accuracy was measured by calibration curve assessment. Furthermore, the model was externally validated using the data of 711 patients enrolled in the same database at different times.Results: Age ≥70 years, Gleason score ≥8, stage T4, stage N1, liver metastases, and Asian/Pacific ethnicity were identified as independent prognostic factors. The C-index of the nomogram for predicting cancer-specific survival (CSS) was 0.68 (95% confidence interval [CI]: 0.65-0.70), with areas under the receiver operating characteristic (ROC) curve (AUCs) for one, three, and five years of 0.70, 0.70, and 0.76, respectively. In the validation cohort, the C-index was 0.66 (95% CI: 0.62 to 0.69), with AUCs for one, three, and five years of 0.67, 0.66 and 0.71, respectively. The calibration curve presented a strong agreement between the nomogram-predicted and actual one-, three-, and five-year CSSs in both the primary and external validation cohorts.Conclusion: We established and validated the first nomogram applied to multiple races for predicting the one-, three-, and five-year CSSs of patients with bone metastatic PCa, which will further facilitate individualized clinical decision-making and will be useful for patient counseling.Funding: This study is supported by the Key Science and Technology Program of Shaanxi Province, PR China (grant number: 2016SF-162) and the Development Funds of Shaanxi Science and Technology Agency of China (grant number:2018SF/091).Declaration of Interest: There are no conflicts of interest.Ethical Approval: The present study conformed to the 1964 Helsinki Declaration and its later amendments and was performed under the ethical standards of the institutional and national research committees.

Nomogram

10.2139/ssrn.3369744

Cite

Citations (0)

Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism

The Aging Male (2023)

Chunlin Wang Hui Zhang Fu Wang Jun Guo Jianlin Yuan

Purpose Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed.

10.1080/13685538.2023.2288347

Cite

Citations (2)

Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy

ESMO Open (2021)

Niuniu Hou Jianfeng Wu Jingjing Xiao Z. Wang Zhi Song

•Establishing the first risk stratification nomogram for BC treated with NAC and validate its performance in BC cohorts.•Incorporating residual cancer burden index into predictive nomogram for the first time.•Predictive model can be utilized to predict DFS for all early-stage BC treated with NAC.•Performing a continuous rather than categorized model to predict individual survival.•The risk stratification can be used to select comparable population in trial design. BackgroundA favorable model for predicting disease-free survival (DFS) and stratifying prognostic risk in breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) is lacking. The aim of the current study was to formulate an excellent model specially for predicting prognosis in these patients.Patients and methodsBetween January 2012 and December 2015, 749 early-stage BC patients who received NAC in Xijing hospital were included. Patients were randomly assigned to a training cohort (n = 563) and an independent cohort (n = 186). A prognostic model was created and subsequently validated. Predictive performance and discrimination were further measured and compared with other models.ResultsClinical American Joint Committee on Cancer stage, grade, estrogen receptor expression, human epidermal growth factor receptor 2 (HER2) status and treatment, Ki-67 expression, lymphovascular invasion, and residual cancer burden were identified as independent prognostic variables for BC treated with NAC. The C-index of the model consistently outperformed other available models as well as single independent factors with 0.78, 0.80, 0.75, 0.82, and 0.77 in the training cohort, independent cohort, luminal BC, HER2-positive BC, and triple-negative BC, respectively. With the optimal cut-off values (280 and 360) selected by X-tile, patients were categorized as low-risk (total points ≤280), moderate-risk (280 < total points ≤ 360), and high-risk (total points >360) groups presenting significantly different 5-year DFS of 89.9%, 56.9%, and 27.7%, respectively.ConclusionsIn patients with BC, the first model including residual cancer burden index was demonstrated to predict the survival of individuals with favorable performance and discrimination. Furthermore, the risk stratification generated by it could determine the risk level of recurrence in whole early-stage BC cohort and subtype-specific cohorts, help tailor personalized intensive treatment, and select comparable study cohort in clinical trials. A favorable model for predicting disease-free survival (DFS) and stratifying prognostic risk in breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) is lacking. The aim of the current study was to formulate an excellent model specially for predicting prognosis in these patients. Between January 2012 and December 2015, 749 early-stage BC patients who received NAC in Xijing hospital were included. Patients were randomly assigned to a training cohort (n = 563) and an independent cohort (n = 186). A prognostic model was created and subsequently validated. Predictive performance and discrimination were further measured and compared with other models. Clinical American Joint Committee on Cancer stage, grade, estrogen receptor expression, human epidermal growth factor receptor 2 (HER2) status and treatment, Ki-67 expression, lymphovascular invasion, and residual cancer burden were identified as independent prognostic variables for BC treated with NAC. The C-index of the model consistently outperformed other available models as well as single independent factors with 0.78, 0.80, 0.75, 0.82, and 0.77 in the training cohort, independent cohort, luminal BC, HER2-positive BC, and triple-negative BC, respectively. With the optimal cut-off values (280 and 360) selected by X-tile, patients were categorized as low-risk (total points ≤280), moderate-risk (280 < total points ≤ 360), and high-risk (total points >360) groups presenting significantly different 5-year DFS of 89.9%, 56.9%, and 27.7%, respectively. In patients with BC, the first model including residual cancer burden index was demonstrated to predict the survival of individuals with favorable performance and discrimination. Furthermore, the risk stratification generated by it could determine the risk level of recurrence in whole early-stage BC cohort and subtype-specific cohorts, help tailor personalized intensive treatment, and select comparable study cohort in clinical trials.

Lymphovascular invasion

Neoadjuvant Therapy

10.1016/j.esmoop.2021.100269

Cite

Citations (6)

Novel survival nomograms for patients with lung metastatic clear cell renal cell carcinoma

Medicine (2020)

Lei Zhang Guangdong Hou Ming Gao Yu Zheng Xinlong Dun

Abstract Survival heterogeneity is observed among renal cell carcinoma (RCC) patients with metastases in different organs. Moreover, almost all previous prognostic nomograms based on data from metastatic RCC patients did not take competing events, such as death from cerebrovascular and heart diseases, into account. We aimed to construct novel prognostic nomograms for patients with lung metastatic clear cell RCC (LMCCRCC). Data of 712 non-Hispanic white LMCCRCC patients registered in the Surveillance, Epidemiology, and End Results database were retrospectively analyzed. Nomograms for predicting overall survival (OS) and disease-specific survival (DSS) were established using the Cox approach and Fine and Gray approach, respectively, and their performances were assessed using the concordance index (C-index), calibration plots, and an independent cohort comprising 181 Hispanic patients. Sex, tumor grade, T stage, N stage, presence or absence of bone metastases, and presence or absence of brain metastases were independent predictors for both OS and DSS. Additionally, presence or absence of liver metastases was an independent predictor only for DSS. Meanwhile, age at diagnosis was independently associated with OS. The C-indexes of the nomograms were 0.702 for OS and 0.723 for DSS in internal validation. In external validation, the C-indexes were 0.700 for OS and 0.708 for DSS. Both internal and external calibration plots showed excellent consistency between the prediction and the observation. The current study developed a novel nomogram for predicting individual OS in LMCCRCC patients. Moreover, we constructed an effective competing risk nomogram for predicting their individual DSS for the first time.

Nomogram

Concordance

10.1097/md.0000000000023465

Cite

Citations (6)

Construction and validation of a novel prognostic nomogram for patients with sarcomatoid renal cell carcinoma: a SEER-based study

International Journal of Clinical Oncology (2020)

Guangdong Hou Xian Li Yu Zheng Pengfei Liu Fei Yan

Nomogram

Concordance

10.1007/s10147-020-01681-2

Cite

Citations (13)

Survival nomogram for patients with upper tract recurrence after resection for localized bladder urothelial carcinoma

Future Oncology (2020)

Guangdong Hou Wanxiang Zheng Wei Zhang Yu Zheng Lei Zhang

Aim: To develop a survival nomogram for patients with upper tract recurrence (UTR) after resection for localized bladder urothelial carcinoma (BUC). Methods: The data of 361 patients with UTR after resection for BUC registered in the Surveillance, Epidemiology, and End Results database were retrospectively analyzed. The nomogram was established using the Fine and Gray method and its predictive accuracy was assessed using the concordance index. The nomogram was calibrated by comparing the predicted and actual survival. Results: The concordance index of the nomogram was 0.746 (95% CI: 0.733–0.759). Excellent agreement was observed between the predicted and actual survival in all calibration plots. Conclusion: This study describes the first survival nomogram for patients experienced UTR after resection for BUC.

Nomogram

Concordance

10.2217/fon-2020-0560

Cite

Citations (1)

Radiotherapy and Increased Risk of Second Primary Cancers in Breast Cancer Survivors: An Epidemiological and Large Cohort Study

The Breast (2024)

Niuniu Hou Zhe Wang Yuwei Ling Guangdong Hou Bo Zhang

Radiotherapy (RT) for breast cancer (BC) may raise the risk of second primary cancers (SPCs), a relationship inadequately studied.

Epidemiology of cancer

10.1016/j.breast.2024.103824

Cite

Citations (0)

Issue Information

Journal of Gastroenterology and Hepatology (2022)

Shiu‐Kum Lam Hong Kong Kunio Okuda Chiba Lawrie William A. Powell

No abstract is available for this article.

10.1111/jgh.16078

Cite

Citations (0)

Establishment and internal validation of preoperative nomograms for predicting the possibility of testicular salvage in patients with testicular torsion

Asian Journal of Andrology (2020)

Wanxiang Zheng Guangdong Hou Wei Zhang Di Wei Xuelin Gao

This study aimed to establish nomograms to preoperatively predict the possibility of testicular salvage (TS) in patients with testicular torsion. The clinical data of 204 patients with testicular torsion diagnosed at Xijing Hospital and Tangdu Hospital (Xi'an, China) between August 2008 and November 2019 were retrospectively analyzed. Univariate and multivariate logistic regression analyses were used to determine the independent predictors of TS. Based on multivariate regression coefficients, nomograms to predict possibility of TS were established. The predictive ability of the nomograms was internally validated by receiver operating characteristic (ROC) curves and calibration plots. The duration of symptoms ranged from 2 h to 1 month, with a median of 3.5 days. Thirty (14.7%) patients underwent surgical reduction and contralateral orchiopexy, while the remaining 174 (85.3%) underwent orchiectomy and contralateral orchiopexy. Finally, long symptom duration was an independent risk predictor for TS, while visible intratesticular blood flow and homogeneous testicular echotexture under color Doppler ultrasound were independent protective predictors. Internal validation showed that the nomograms, which were established by integrating these three predictive factors, had good discrimination ability in predicting the possibility of TS (areas under the ROC curves were 0.851 and 0.828, respectively). The calibration plots showed good agreement between the nomogram-predicted possibility of TS and the actual situation. In conclusion, this brief preoperative prediction tool will help clinicians to quickly determine the urgency of surgical exploration.

Nomogram

Orchiopexy

Univariate

Univariate analysis

Orchiectomy

10.4103/aja.aja_31_20

Cite

Citations (8)